Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/DHX36_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DHX36_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DHX36_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DHX36_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DHX36_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DHX36_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DHX36_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DHX36_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00107208 | Prostate | BPH | positive regulation of cell development | 86/3107 | 298/18723 | 7.11e-08 | 1.85e-06 | 86 |
GO:00313469 | Prostate | BPH | positive regulation of cell projection organization | 98/3107 | 353/18723 | 7.34e-08 | 1.88e-06 | 98 |
GO:200125214 | Prostate | BPH | positive regulation of chromosome organization | 34/3107 | 82/18723 | 8.14e-08 | 2.05e-06 | 34 |
GO:003220610 | Prostate | BPH | positive regulation of telomere maintenance | 25/3107 | 52/18723 | 1.34e-07 | 3.18e-06 | 25 |
GO:000961510 | Prostate | BPH | response to virus | 99/3107 | 367/18723 | 2.82e-07 | 6.07e-06 | 99 |
GO:003465515 | Prostate | BPH | nucleobase-containing compound catabolic process | 107/3107 | 407/18723 | 3.79e-07 | 7.89e-06 | 107 |
GO:000940815 | Prostate | BPH | response to heat | 40/3107 | 110/18723 | 4.27e-07 | 8.77e-06 | 40 |
GO:00015039 | Prostate | BPH | ossification | 107/3107 | 408/18723 | 4.31e-07 | 8.83e-06 | 107 |
GO:00322005 | Prostate | BPH | telomere organization | 52/3107 | 159/18723 | 4.40e-07 | 8.92e-06 | 52 |
GO:00609966 | Prostate | BPH | dendritic spine development | 37/3107 | 99/18723 | 5.22e-07 | 1.04e-05 | 37 |
GO:00163589 | Prostate | BPH | dendrite development | 71/3107 | 243/18723 | 5.73e-07 | 1.14e-05 | 71 |
GO:000926610 | Prostate | BPH | response to temperature stimulus | 56/3107 | 178/18723 | 6.74e-07 | 1.30e-05 | 56 |
GO:001083310 | Prostate | BPH | telomere maintenance via telomere lengthening | 32/3107 | 81/18723 | 7.19e-07 | 1.37e-05 | 32 |
GO:004348714 | Prostate | BPH | regulation of RNA stability | 54/3107 | 170/18723 | 7.56e-07 | 1.43e-05 | 54 |
GO:00072499 | Prostate | BPH | I-kappaB kinase/NF-kappaB signaling | 79/3107 | 281/18723 | 7.61e-07 | 1.43e-05 | 79 |
GO:00342494 | Prostate | BPH | negative regulation of cellular amide metabolic process | 77/3107 | 273/18723 | 9.10e-07 | 1.67e-05 | 77 |
GO:190435810 | Prostate | BPH | positive regulation of telomere maintenance via telomere lengthening | 19/3107 | 37/18723 | 1.20e-06 | 2.12e-05 | 19 |
GO:19033138 | Prostate | BPH | positive regulation of mRNA metabolic process | 41/3107 | 118/18723 | 1.23e-06 | 2.16e-05 | 41 |
GO:001077010 | Prostate | BPH | positive regulation of cell morphogenesis involved in differentiation | 31/3107 | 79/18723 | 1.27e-06 | 2.22e-05 | 31 |
GO:007121410 | Prostate | BPH | cellular response to abiotic stimulus | 89/3107 | 331/18723 | 1.28e-06 | 2.23e-05 | 89 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DHX36 | SNV | Missense_Mutation | novel | c.2971N>A | p.Glu991Lys | p.E991K | Q9H2U1 | protein_coding | deleterious(0.02) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DHX36 | SNV | Missense_Mutation | | c.319N>A | p.Asp107Asn | p.D107N | Q9H2U1 | protein_coding | tolerated(0.31) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DHX36 | SNV | Missense_Mutation | rs151135113 | c.1070N>A | p.Arg357Gln | p.R357Q | Q9H2U1 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | novel | c.2400G>C | p.Gln800His | p.Q800H | Q9H2U1 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-B6-A402-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PD |
DHX36 | SNV | Missense_Mutation | novel | c.140N>A | p.Arg47Gln | p.R47Q | Q9H2U1 | protein_coding | tolerated(0.59) | possibly_damaging(0.885) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | novel | c.875N>T | p.Tyr292Phe | p.Y292F | Q9H2U1 | protein_coding | tolerated(0.12) | probably_damaging(0.979) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DHX36 | insertion | Nonsense_Mutation | novel | c.1464_1465insTAATTATTTATTTATTAATTTATTTTTGAAAC | p.Gly489Ter | p.G489* | Q9H2U1 | protein_coding | | | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD |
DHX36 | SNV | Missense_Mutation | novel | c.418N>T | p.Leu140Phe | p.L140F | Q9H2U1 | protein_coding | tolerated(0.73) | benign(0) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
DHX36 | SNV | Missense_Mutation | rs747063807 | c.1949N>A | p.Gly650Glu | p.G650E | Q9H2U1 | protein_coding | tolerated(0.71) | benign(0.007) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
DHX36 | SNV | Missense_Mutation | novel | c.1003G>A | p.Glu335Lys | p.E335K | Q9H2U1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |